Beijing akan mendorong penggunaan obat inovatif, perangkat medis, dan robot bedah di rumah sakit

7 April, Beijing Municipal Medical Security Bureau and ten other departments jointly released the “Several Measures to Support High-Quality Development of Innovative Medicine in Beijing (2026)” (hereinafter referred to as “Measures 2026 Edition”), further accelerating innovation in the city’s pharmaceutical and health industry, implementing a rolling high-quality development action for the industrial chain, continuously building a support system covering “research and development—approval—production—application,” providing precise, stable, and predictable policy environment for innovative drug and medical device companies, and fully stimulating the development momentum of new quality productivity. It explicitly states that innovative drugs, medical devices, and surgical robots will be promoted for hospital use.

It is understood that the Measures 2026 Edition includes 32 new initiatives, adhering to Beijing (Jing-Jin-Ji) International Science and Technology Innovation Center’s leading role, staying at the forefront of pharmaceutical technology development, and laying out source innovation. For example, in AI artificial intelligence prediction, organoids and organ chips, developing no less than 15 models; in immunotherapy and drug research and development, building high-level R&D platforms to promote clinical transformation applications, discovering new targets, and developing candidate drugs. Focusing on complex coronary artery disease intervention, precise radiotherapy for complex tumors, non-vitrectomy removal of macular epiretinal membrane, etc., conducting key core technology research and transformation of medical robots. Cultivating a group of internationally influential project leaders capable of leading multi-center international clinical trials.

Meanwhile, a series of support policies for pharmaceutical manufacturing are proposed, including enhancing industrial platform service levels, expanding production of drugs and medical devices, and accelerating digital and intelligent transformation of the pharmaceutical industry. Also proposed are tasks such as supporting no less than 120 international multi-center clinical trials, tackling weak links in process materials and components through collaborative efforts, promoting at least 18 newly approved innovative drugs and medical devices, and promoting hospital use of innovative drugs, medical devices, and surgical robots. Actively supporting regulatory science research, strengthening intellectual property protection in the pharmaceutical field, leveraging commercial health insurance support, and comprehensively promoting high-quality development of innovative medicine.

It is understood that since 2024, the city has consecutively issued the “Several Measures to Support High-Quality Development of Innovative Medicine in Beijing” for two years, achieving remarkable results. In 2025, the average time to start clinical trial projects was 21.6 weeks, nearly 11 weeks shorter than in 2023; a total of 215 global synchronized clinical trials were conducted throughout the year. Sixteen innovative drugs and medical devices were newly approved, including 6 innovative drugs and 10 Class III medical devices. Johnson & Johnson’s “Nicalimab Injection” became the first biological product nationwide approved for phased production pilot. 674 nationally renowned innovative drugs were directly included in designated medical institution drug lists, and Beijing’s inclusive health insurance drug list increased to 159 items. The pharmaceutical and health industry scale reached 1.13 trillion yuan, a year-on-year increase of 6.5%. Major industrial projects such as Sanofi’s insulin raw material production base and Eli Lilly-Kanglong ChemPharm’s local production of Olfeglitazone tablets have landed in Beijing, with over 20 key pharmaceutical companies like Novartis, AstraZeneca, and Johnson & Johnson expanding investments or establishing R&D centers in the city.

The Beijing Medical Security Bureau stated that the next step will be to strengthen cross-departmental coordination and data sharing, comprehensively enhance the original innovation capacity of pharmaceutical technology and clinical service supply efficiency, and effectively improve people’s sense of gain, happiness, and safety regarding high-quality medical services.

Source: Beijing Youth Daily Client

Author: Xie Li

Massive information, precise interpretation, all on Sina Finance APP